

US 03/17382

REC'D 19 AUG 2003

WIPO PCT

P2 1031539

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

August 11, 2003


THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: *PCT/US02/17006*

FILING DATE: *May 29, 2002*

RELATED PCT APPLICATION NUMBER: *PCT/US03/17382*

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



P. Swain
P. SWAIN
Certifying Officer

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

**TRANSMITTAL LETTER TO THE
UNITED STATES RECEIVING OFFICE**

Date	29 May 2002
International Application No.	PCT/US 02/17006
Attorney Docket No.	100788.0011PCT

Certification under 37 CFR 1.10 (if applicable)

JO20 Rec'd PCT/PTO 29 MAY 2002

EV062683358US
Express Mail mailing number

29 May 2002
Date of Deposit

I hereby certify that the application/correspondence attached hereto is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of person mailing correspondence
--

Erika Simpson
Typed or printed name of person mailing correspondence

☒ New International Application

TITLE	Integrated Micro Array System and Methods Therefor
-------	--

Earliest priority date (Day/Month/Year)
--

SCREENING DISCLOSURE, INFORMATION: In order to assist in screening the accompanying international application for purposes of determining whether a license for foreign transmittal should and could be granted and for other purposes, the following information is supplied. (Note: check as many boxes as apply):

- A. ☐ The invention disclosed was not made in the United States.
- B. ☒ There is no prior U.S. application relating to this invention.
- C. ☐ The following prior U.S. application(s) contain subject matter which is related to the invention disclosed in the attached international application. (NOTE: priority to these applications may or may not be claimed on form PCT/RO/101 (Request) and this listing does not constitute a claim for priority.)

application no.		filed on	
application no.		filed on	

- D. ☐ The present international application contains additional subject matter not found in the prior U.S. application(s) identified in paragraph C. above. The additional subject matter is found on pages _____ and ☐ DOES NOT ALTER ☐ MIGHT BE CONSIDERED TO ALTER the general nature of the invention in a manner which would require the U.S. application to have been made available for inspection by the appropriate defense agencies under 35 U.S.C. 181 and 37 CFR 5.1. See 37 CFR 5.15

☐ A Response to an Invitation from the RO/US. The following document(s) is(are) enclosed:

- A. ☐ A Request for An Extension of Time to File a Response
- B. ☐ A Power of Attorney (General or Regular)
- C. ☐ Replacement pages:

pages		of the request (PCT/RO/101)	pages		of the figures
pages		of the description	pages		of the abstract
pages		of the claims			

- D. ☐ Submission of Priority Documents


Priority document		Priority document	
-------------------	--	-------------------	--

- E. ☐ Fees as specified on attached Fee Calculation sheet form PCT/RO/101 annex

☐ A Request for Rectification under PCT 91 ☐ A Petition ☐ A Sequence Listing Diskette

☐ Other (please specify):

person
ing this
n is the:

<input type="checkbox"/> Applicant	Robert D. Fish	Typed name of signer
<input checked="" type="checkbox"/> Attorney/Agent (Reg. No.) 33880		
<input type="checkbox"/> Common Representative	Signature	

HOME COPY

USDP 171126

1/5

PCT REQUEST

788.11PCT

Original (for SUBMISSION) - printed on 29.05.2002 01:43:40 PM

0	For receiving Office use only	
0-1	International Application No.	PCT/US 02/17006
0-2	International Filing Date	29 MAY 2002 (29.05.02)
0-3	Name of receiving Office and "PCT International Application"	PCT INTERNATIONAL APPLICATION RO/US
0-4	Form - PCT/RO/101 PCT Request	
0-4-1	Prepared using	PCT-EASY Version 2.92 (updated 01.01.2002)
0-5	Petition The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty	
0-6	Receiving Office (specified by the applicant)	United States Patent and Trademark Office (USPTO) (RO/US)
0-7	Applicant's or agent's file reference	788.11PCT
I	Title of invention	INTEGRATED MICRO ARRAY SYSTEM AND METHODS THEREFOR
II	Applicant	
II-1	This person is:	applicant only
II-2	Applicant for	all designated States except US
II-4	Name	AUTOGENOMICS, INC.
II-5	Address:	2270-K Camino Vida Roble Carlsbad, CA 92009 United States of America
II-6	State of nationality	US
II-7	State of residence	US
II-8	Telephone No.	760-804-7378
II-9	Facsimile No.	760-804-7382
III-1	Applicant and/or inventor	
III-1-1	This person is:	applicant and inventor
III-1-2	Applicant for	US only
III-1-4	Name (LAST, First)	KURESHY, Fareed
III-1-5	Address:	Autogenomics, Inc. 2132 Pinar Place Del Mar, CA 92014 United States of America
III-1-6	State of nationality	US
III-1-7	State of residence	US

PCT REQUEST

788.11PCT


Original (for SUBMISSION) - printed on 29.05.2002 01:43:40 PM

III-2	Applicant and/or inventor	
III-2-1	This person is:	applicant and inventor
III-2-2	Applicant for	US only
III-2-4	Name (LAST, First)	MAHANT, Vijay
III-2-5	Address:	Autogenomics, Inc. 42299 Wild Mustang Road Murrieta, CA 92562 United States of America
III-2-6	State of nationality	US
III-2-7	State of residence	US
III-3	Applicant and/or inventor	
III-3-1	This person is:	applicant and inventor
III-3-2	Applicant for	US only
III-3-4	Name (LAST, First)	SINGH, Shailendra
III-3-5	Address:	Autogenomics, Inc. 125 Furnace Street Sharon, MA 02067 United States of America
III-3-6	State of nationality	US
III-3-7	State of residence	US
IV-1	Agent or common representative; or address for correspondence	
	The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:	agent
IV-1-1	Name	RUTAN & TUCKER LLP
IV-1-2	Address:	611 Anton Blvd., Suite 1400 Costa Mesa, CA 92626 United States of America
IV-1-3	Telephone No.	714-641-5100
IV-1-4	Facsimile No.	714-546-9035
IV-2	Additional agent(s)	
IV-2-1	Name(s)	additional agent(s) with same address as first named agent FISH, Robert(33880); ZOETEWEEY, David(45258); THOMPSON, Sandie(46264); FESSENMAIER, Martin(46697)

V	Designation of States	
V-1	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	AP: GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW and any other State which is a Contracting State of the Harare Protocol and of the PCT EA: AM AZ BY KG KZ MD RU TJ TM and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT EP: AT BE CH&LI CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR and any other State which is a Contracting State of the European Patent Convention and of the PCT OA: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG and any other State which is a member State of OAPI and a Contracting State of the PCT
V-2	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	AE AG AL AM AT (patent and utility model) AU AZ BA BB BG BR BY BZ CA CH&LI CN CO CR CU CZ (patent and utility model) DE (patent and utility model) DK (patent and utility model) DM DZ EC EE (patent and utility model) ES FI (patent and utility model) GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK (patent and utility model) SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
V-5	Precautionary Designation Statement In addition to the designations made under items V-1, V-2 and V-3, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except any designation(s) of the State(s) indicated under item V-6 below. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit.	
V-6	Exclusion(s) from precautionary designations	NONE
VI	Priority claim	NONE
VII-1	International Searching Authority Chosen	United States Patent and Trademark Office (USPTO) (ISA/US)

PCT REQUEST

Original (for SUBMISSION) - printed on 29.05.2002 01:43:40 PM

VIII	Declarations	Number of declarations	
VIII-1	Declaration as to the identity of the inventor	-	
VIII-2	Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent	-	
VIII-3	Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application	-	
VIII-4	Declaration of inventorship (only for the purposes of the designation of the United States of America)	-	
VIII-5	Declaration as to non-prejudicial disclosures or exceptions to lack of novelty	-	
IX	Check list	number of sheets	electronic file(s) attached
IX-1	Request (including declaration sheets)	5	-
IX-2	Description	25	-
IX-3	Claims	6	-
IX-4	Abstract	1	EZABST00.TXT
IX-5	Drawings	6	-
IX-7	TOTAL	43	
	Accompanying items	paper document(s) attached	electronic file(s) attached
IX-8	Fee calculation sheet	✓	-
IX-11	Copy of general power of attorney	reference no. 788.11PCT	-
IX-17	PCT-EASY diskette	-	Diskette
IX-19	Figure of the drawings which should accompany the abstract	1A	
IX-20	Language of filing of the international application	English	
X-1	Signature of applicant, agent or common representative		
X-1-1	Name (LAST, First)	FISH, Robert	

FOR RECEIVING OFFICE USE ONLY

(29.05.02)

10-1	Date of actual receipt of the purported international application	IC20 PCT/PTO 29 MAY 2002
10-2	Drawings:	
10-2-1	Received	
10-2-2	Not received	
10-3	Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application	
10-4	Date of timely receipt of the required corrections under PCT Article 11(2)	
10-5	International Searching Authority	ISA/US

PCT 115132 1 2005

5/5

PCT REQUEST

788.11PCT

Original (for SUBMISSION) - printed on 29.05.2002 01:43:40 PM

10-6	Transmittal of search copy delayed until search fee is paid	
------	--	--

FOR INTERNATIONAL BUREAU USE ONLY

11-1	Date of receipt of the record copy by the International Bureau	
------	---	--

PCT (ANNEX - FEE CALCULATION SHEET)

788.11PCT

Original (for SUBMISSION) - printed on 29.05.2002 01:43:40 PM

(This sheet is not part of and does not count as a sheet of the International application)

0	For receiving Office use only	
0-1	International Application No.	PCT/US 02/17006
0-2	Date stamp of the receiving Office	29 MAY 2002 (29.05.02)
0-4	Form - PCT/RO/101 (Annex)	
0-4-1	PCT Fee Calculation Sheet Prepared using	PCT-EASY Version 2.92 (updated 01.01.2002)
0-9	Applicant's or agent's file reference	788.11PCT
2	Applicant	AUTOGENOMICS, INC., et al.
12	Calculation of prescribed fees	fee amount/multiplier Total amounts (USD)
12-1	Transmittal fee T ⇨	240 240
12-2-1	Search fee S ⇨	700 700
12-2-2	International search to be carried out by	US
12-3	International fee	
	Basic fee	
	(first 30 sheets) b1 407	
12-4	Remaining sheets 13	
12-5	Additional amount (X) 9	
12-6	Total additional amount b2 117	
12-7	b1 + b2 = B 524	
12-8	Designation fees	
	Number of designations contained in international application 93	
12-9	Number of designation fees payable (maximum 5) 5	
12-10	Amount of designation fee (X) 88	
12-11	Total designation fees D 440	
12-12	PCT-EASY fee reduction R -125	
12-13	Total International fee (B+D-R) I ⇨	839 839
12-17	TOTAL FEES PAYABLE (T+S+I+P) ⇨	1,779 1779
12-19	Mode of payment	cheque
12-20	Deposit account instructions	
	The receiving Office:	United States Patent and Trademark Office (USPTO) (RO/US)
12-20-2	Authorization to charge any deficiency or credit any overpayment in the total fees indicated above.	<input checked="" type="checkbox"/>
12-20-3	Authorization to charge the fee for priority document.	<input checked="" type="checkbox"/>
12-21	Deposit account No.	502191
12-22	Date	29 May 2002 (29.05.2002)

8780211006

2/2

PCT (ANNEX - FEE CALCULATION SHEET)

788.11PCT

Original (for **SUBMISSION**) - printed on 29.05.2002 01:43:40 PM

12-23	Name and signature	FISH, Robert
-------	--------------------	--------------

VALIDATION LOG AND REMARKS

13-2-4	Validation messages Priority	Green? No priority of an earlier application has been claimed. Please verify
--------	---------------------------------	--

PCT

GENERAL POWER OF ATTORNEY

(for several international applications filed under the Patent Cooperation Treaty)

(PCT Rule 90.5)

The undersigned person(s)
(Family name followed by given name, for a legal entity, full official designation The address must include postal code and name of country.)

AUTOGENOMICS, INC
2270-K, Camino Vida Roble
Carlsbad, CA 92009
US

hereby appoints (appoint) the following person as:

☒ agent

☐ common representative

Name and address
(Family name followed by given name, for a legal entity, full official designation The address must include postal code and name of country.)

FISH, Robert D.
Rutan & Tucker LLP
611 Anton Blvd., Suite 1400
Costa Mesa, CA 92626
US

to represent the undersigned before

☒

all the competent International Authorities

☐

the International Searching Authority only

☐

the International Preliminary Examining Authority only


in connection with any and all international applications filed by the undersigned with the following Office

US PTO

as receiving Office

and to make or receive payments on behalf of the undersigned

Signatures of the applicant(s) (where there are several persons, each of them must sign, read as the signature, indicate the name of the person signing and the capacity in which the person signs if such capacity is not obvious from reading the power)



Vijay Mahant, Vice President

Date: 1/23/02

Form PCT/Model of general power of attorney (for several international applications) (July 1992)

PCT

GENERAL POWER OF ATTORNEY

(for several international applications filed under the Patent Cooperation Treaty)

(PCT Rule 90.5)

The undersigned person(s)
(Family name followed by given name; for a legal entity, full official designation The address must include postal code and name of country)

KURESHY, Fareed
2132 Pinar Place
Del Mar, Ca 92014
US

hereby appoints (appoints) the following person as:

☒ agent

☐ common representative

Name and address
(Family name followed by given name; for a legal entity, full official designation The address must include postal code and name of country)

FISH, Robert D.
Rutan & Tucker LLP
611 Anton Blvd., Suite 1400
Costa Mesa, CA 92626
US

to represent the undersigned before

☒

all the competent international Authorities

☐

the International Searching Authority only

☐

the International Preliminary Examining Authority only

in connection with any and all international applications filed by the undersigned with the following Office

US PTO

as receiving Office

and to make or receive payments on behalf of the undersigned.

Signature of the applicant(s) (where there are several persons, each of them must sign; add to the signature, indicate the name of the person signing and the capacity in which the person signs, if such capacity is not obvious from context and power)

Fareed Kureshy

Fareed Kureshy, Inventor

Date: January 22nd 2002

Form PCT/Model of general power of attorney (for several international applications) (July 1992)

PCT

GENERAL POWER OF ATTORNEY

(for several international applications filed under the Patent Cooperation Treaty)

(PCT Rule 90.5)

The undersigned person(s)
(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country)

MAHANT, Vijay
42299 Wild Mustang Road
Murieta, CA 92562
US

hereby appoints (appoints) the following person as:

☒ agent

☐ common representative

Name and address
(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country)

FISH, Robert D.
Rutan & Tucker LLP
611 Anton Blvd., Suite 1400
Costa Mesa, CA 92626
US

to represent the undersigned before

☒

all the competent International Authorities

☐

the International Searching Authority only

☐

the International Preliminary Examining Authority only

in connection with any and all international applications filed by the undersigned with the following Office

US PTO

as receiving Office

and to make or receive payments on behalf of the undersigned

Signatures of the applicant(s) (where there are several persons, each of them must sign; next to the signature, indicate the name of the person signing and the capacity in which the person signs, if such capacity is not obvious from reading the power)

Vijay Mahant

Vijay Mahant, Inventor

Date

1/23/02

Form PCT/Model of general power of attorney (for several international applications)(July 1992)

PCT

GENERAL POWER OF ATTORNEY

(for several international applications filed under the Patent Cooperation Treaty)

(PCT Rule 90.5)

The undersigned person(s)
(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

SINGH, Shailendra
125 Furnace Street
Sharon, MA 02067
US

hereby appoints (appoint) the following person —

☒ agent

☐ common representative

Name and address
(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

FISH, Robert D.
Rutan & Tucker LLP
611 Anton Blvd., Suite 1400
Costa Mesa, CA 92626
US

to represent the undersigned before

☒ all the competent International Authorities

☐ the International Searching Authority only

☐ the International Preliminary Examining Authority only

in connection with any and all international applications filed by the undersigned with the following Office

US PTO

as receiving Office

and to make or receive payments on behalf of the undersigned

Signatures of the applicant(s) (before them, the several persons, each of them (which sign) read to the signature, indicate the name of the person signing and the capacity in which the person signs. If such capacity is not covered from reading the power)


Shailendra Singh, Inventor

Date

1/23/02

Form PCT/Model of General power of attorney (for several international applications)(July 1992)

P. 0001

Attorney Docket No.: 100788.0011PCT

- 1 -

INTEGRATED MICRO ARRAY SYSTEM AND METHODS THEREFOR

Field of The Invention

The field of the invention is micro array systems, and particularly automated micro array systems.

Background of The Invention

Recent advances in genomics and proteomics research made numerous nucleotide and peptide sequences available, necessitating high-throughput screening of samples for presence and/or quantity of genes and/or gene expression. While automation of individual steps (*e.g.*, DNA isolation, protein fractionation, etc.) in high-throughput screening may be performed using relatively simple instrument configurations, integration of multiple and distinct steps in automated high-throughput screening remains problematic.

For example, sample analysis for detection and quantification of one or more analytes may be performed in nano-volumes on a single chip (see *e.g.*, "Lab-on-a-chip" from Agilent or Caliper Technologies). Such multiple analyte detection can advantageously be performed in relatively short time using minimal amounts of sample. Moreover, all steps from handling of the sample after application of the sample to detection and analysis are performed within the same device. However, identification and quantification of the detected analyte using nanoelectrophoresis is typically restricted to the size of the analyte. Moreover, resolution of individual analytes becomes increasingly difficult as the size or charge difference between the analytes decreases. Consequently, such nanoelectrophoretic systems are generally limited to characterization of an analyte by its molecular weight.

Where high resolution of molecular weights of an analyte is particularly important, analysis of complex samples may be coupled with laser desorption - time of flight mass spectroscopic analysis (see *e.g.*, Ciphergen Biosystems' LD-TOF multi-analyte desorption chips, or Sequenom chip). Here, components of a complex sample are immobilized on a carrier chip (*e.g.*, chip with anion exchange resin or hydrophobic interaction resin) and subjected to size analysis after desorption according to their molecular properties in an analysis system. LD-TOF coupled analysis is typically highly sensitive and often requires

only minimal sample preparation. Moreover, LD-TOF coupled analysis provides relatively high resolution among particular analytes. However, identification of particular analytes is still mostly limited to size determination.

Alternatively, and especially where the analyte is a DNA or RNA, various formats of automated modular PCR-based analysis are known in the art. For example, where a single sample is analyzed for presence or absence of a particular sequence, all or almost all of the reagents and sample may be introduced into an automated system from a single cartridge (see *e.g.*, Cepheid's i-CORE system). On the other hand, and especially where a relatively high number of samples are concurrently analyzed, a full robotic PCR station may be employed (see *e.g.*, Orchid Biocomputer SNP Analysis system). Such systems typically provide an analysis procedure that integrates sample manipulation with nucleic acid amplification and product analysis. However, automated modular PCR-based analysis typically rely on amplification of target DNA to generate appreciable signals, thereby introducing significant complexity and numerous error-prone procedures. Moreover, while PCR based systems are frequently operated in a dedicated environment using dedicated equipment to prevent non-sample specific signals, problems associated with contamination via sample carry-over may still persist. Thus, automated modular PCR-based analysis tends to be highly expensive, and is generally limited to exclusive analysis of nucleic acids.

In still further examples, nucleic acid-containing samples can be analyzed by their hybridization characteristics with at least partially complementary and immobilized nucleic acids, thereby providing quantitative and qualitative information on a particular sample. Hybridization of a nucleic acid to corresponding solid-phase immobilized nucleic acids may be controlled by variation of temperature and/or ionic strength of the environment of the nucleic acid hybrid, and there are numerous systems known in the art.

For example, high density arrays of immobilized oligonucleotides on a silicon chip may be exposed to a sample containing nucleic acids that are complementary to at least some of the immobilized oligonucleotides (see *e.g.*, Affymetrix' GeneChip system). In such systems, a processed sample (typically a labeled and biotinylated in-vitro transcript of a previously prepared cDNA) is provided to the chip in a fluidics station that further controls

PCT

Attorney Docket No.: 100788.0011PCT

- 3 -

flow of reagents and hybridization temperature. After complementary labeled nucleic acids have hybridized to the corresponding nucleic acids on the chip, the chip is removed from the fluidics station and manually transferred to a scanner station in which the sample is analyzed via detection of the fluorescent labels. While such analytic devices typically allow a user to determine identity, presence, and/or quantity of a vast number of DNA/RNA analytes in a sample, substantial sample preparation (typically several hours to more than one day) and hybridization times (*e.g.*, about 16 hours at 40°C) are frequently necessary. Moreover, analytes detected and quantified using such systems tend to be limited to nucleic acids.

Alternatively, sample capture and hybridization may be controlled via electrostatic forces (see *e.g.*, Nanogen's NanoChip system). In such systems, capture probes and hybridization conditions may be individually controlled, thereby allowing custom addressing of individual analyte pixels. However, due to the complexity of loading and reading procedures, the analytic process is split among at least two independent devices: Analytes are typically bound in a loader section, while a reader (*i.e.*, array processor and scanner) will perform the readout of the sample.

In another system, detection may be performed using an electronic chip that provides a signal upon binding of a signaling oligonucleotide to an analyte oligonucleotide that is bound to a corresponding oligonucleotide that is immobilized on the chip (see *e.g.*, Motorola's iSensor system). While electronic detection and quantification may provide at least some advantages, most of such systems are prone to non-specific false-positive and/or false-negative signals due to contamination. Moreover, analytes detected and quantified using such systems tend to be limited to nucleic acids.

Thus, although various systems for micro array systems are known in the art, numerous problems still remain. Among other things, while various systems may provide at least some automation, fluid handling and sample detection/quantification of analyte binding are typically operated in separate devices, thus requiring at least some user intervention after the sample is applied to the system. Furthermore, all or almost all of the known micro array systems are limited to analysis of either nucleic acids or peptides. Therefore, there is still a need for an improved methods and systems for automated analytic devices.

PATENT

Attorney Docket No.: 100788.0011PCT

- 4 -

Summary of the Invention

The present invention is directed to methods of operating analytical devices, and especially to methods of operating automated micro array systems that allow fully automated sample processing and detection/quantification of various analytes (*e.g.*, nucleic acid, protein samples, low molecular weight compounds, etc.) in a single analytical device.

In one aspect of the inventive subject matter, a method of analyzing an analyte on a biochip has one step in which an analytical device is provided that includes a first section and a second section that receive a biochip having a plurality of substrates in a plurality of predetermined positions. In another step, the biochip is contacted in the first section with a sample containing a non-analyte and an analyte under conditions that allow binding of the analyte to at least one of the substrates, and in a still another step, the first section is operationally to the second section such that the biochip is automatically transferred from the first section to the second section. In a further step, binding of the analyte to the at least one of the substrates on the biochip is optically detected in the second section.

Contemplated biochips may be provided to the first section from a magazine using an automatic actuator, wherein the magazine is disposed within the analytical device, and it is further preferred that the first section may be configured to receive at least a second biochip. The first section may additionally include an energy source (*e.g.*, ultrasound, microwave, and/or heat/cool source). Contemplated samples may include biological fluids with tissue, nucleic acids, peptides, and/or enzyme inhibitor as analytes. Consequently, suitable substrates include nucleic acids, peptides, and/or enzymes, which may or may not be non-covalently coupled to the biochip via a crosslinker.

Preferred steps of contacting may include pipetting the sample with an automatic pipette that is disposed within the analytical device, wherein the biochip may or may not be heated. Especially contemplated steps of operationally coupling include providing an automatic actuator that moves the biochip from a first platform of the first section to a second platform of a second section, while preferred steps of optically detecting include detection of a fluorescence signal, a chemiluminescence signal, and/or a phosphorescence

PATENT

Attorney Docket No.: 100788.001 PCT

- 5 -

signal with a confocal microscope or a dark field microscope, which may be focused using a reference signal from a reference marker that is disposed on the biochip.

In another aspect of the inventive subject matter, a method of analyzing an analyte on a biochip may include one step in which a biochip with a reference marker and a plurality of substrates is provided, wherein at least one of the substrates binds an analyte. In another step, the reference marker (*e.g.*, comprising a fluorophor, luminogenic substrate, and/or a phosphorescent compound) is illuminated to create a reference signal, and the analyte is illuminated to create an analyte signal. In yet another step, a focal plane is determined for an optical detector using the reference signal and adjusting the optical detector to the focal plane, and in a further step, the analyte signal is acquired using the optical detector.

Preferred illumination of the reference marker and/or the analyte includes dark field illumination, and illumination of the analyte with a laser is particularly preferred. Further especially contemplated illuminations for the reference marker and the analyte may be performed using independent light sources.

In a further aspect of the inventive subject matter, a method of operating an analytical includes one step in which an analytical device is provided comprising a data transfer interface coupled to a detector, a multi-reagent pack, an automatic pipette, and/or a sample processing platform. In another step, the data transfer interface is electronically coupled with a person other than a user of the analytical device, and in still another step, data are provided from the detector, the multi-reagent pack, the automatic pipette, and/or the sample processing platform to the person via the data transfer interface. In a further step, the data are employed to analyze operational status of the analytical device.

Particularly preferred methods of operation include those in which the person other than the user is in a remote location relative to the analytical device, and in which the step of providing is executed via an Internet or via a modem connection. Data may be provided in response to an action of the user of the analytical device, or in response to a request by the person other than the user. Contemplated data may relate to the batch number, date manufactured, expiration date, or type of reagent in the multi-reagent pack, volume of the

PATENT

Attorney Docket No.: 100788.0011PCT

- 6 -

reagent in the multi-reagent pack, volume of liquid transferred using the automatic pipette, temperature of the sample processing platform, type of test performed using the analytical device. Consequently, operational status of the analytical device may include inoperability of one or more components and/or lack of one or more reagents.

In yet another aspect of the inventive subject matter, a method of marketing includes one step in which an analytical device is provided comprising a data transfer interface that receives status data of a component in the analytical device. In another step, the data transfer interface is electronically coupled with a system in a remote location relative to the analytical device, and in yet another step, status data are provided to the remote system using the data transfer interface. In a still further step, the status data are used in the remote system to initiate delivery of a replacement for the component.

Especially contemplated analytical devices analyze binding of an analyte to a substrate on a biochip, and particularly contemplated components include reagents, wherein the status data of the component is the volume of the reagent in the analytical device. Electronic coupling may be performed via modem or other data transfer connection to the Internet, and delivery of the status data may be controlled by a predetermined schedule executed on a processor of the analytical device or by a predetermined schedule executed on a processor of the system in the remote location. Especially preferred initiation of delivery includes automatic generation of a purchase order or inventory control (*e.g.*, packaging and/or labeling of the component, or alert to the customer to indicate status/low supply of the component).

Various objects, features, aspects and advantages of the present invention will become more apparent from the following detailed description of preferred embodiments of the invention, along with the accompanying drawings in which like numerals represent like components.

PATENT

Attorney Docket No.: 100788.0011PCT

- 7 -

Brief Description of The Drawing

Figure 1A is a schematic view of an exemplary analytical device according to the inventive subject matter.

Figure 1B is a perspective view of an exemplary analytical device according to the inventive subject matter.

Figure 2 is a flow chart of a method of analyzing an analyte on a biochip according to the inventive subject matter.

Figure 3 is a flow chart of another method of analyzing an analyte on a biochip according to the inventive subject matter.

Figure 4 is a flow chart of a method of operating an analytical device according to the inventive subject matter.

Figure 5 is a flow chart of a method of marketing according to the inventive subject matter.

Detailed Description

The inventors discovered that one or more analytes can be detected and/or quantified using an integrated analytical device that employs a biochip, wherein (a) processing of the analyte and/or biochip, detection and/or quantification of the analyte is integrated into a process that does not require user intervention, and (b) the integrated analytical device is configured to allow concurrent or subsequent analysis of various biochemically diverse analytes, including nucleic acids, peptides, and small molecules (e.g., enzyme substrates or inhibitors, etc.).

As used herein, the term "analytical device" refers to any device or combination of devices that is employed to detect and/or quantify one or more analytes. Particularly preferred analytical devices include micro array systems, wherein the term "micro array system" refers to an integrated system in which a plurality of analytes are bound to a

plurality of substrates on a biochip in predetermined positions, and in which presence and/or quantity of at least one of the analytes is determined.

As also used herein, the term "biochip" generally refers to a carrier upon which a plurality of substrates are immobilized in predetermined positions, and wherein at least one of the substrates binds an analyte from a sample. One class of particularly preferred biochips includes a carrier coupled to a multi-functional matrix layer that is coupled to a substrate, wherein the multi-functional matrix layer provides reduction of at least one of an autofluorescence of the carrier, an incident-light-absorption of the carrier, a charge-effect of the carrier, and a surface unevenness of the carrier, and wherein the substrate binds to an analyte that is disposed in a sample fluid when the sample fluid contacts the biochip.

Alternatively, another class of especially contemplated biochips comprises a plurality of first substrates in a plurality of first predetermined positions, wherein each of the plurality of first substrates belongs to a class selected from the group consisting of a polypeptide, a polynucleotide, a carbohydrate, and a pharmacologically active molecule. A plurality of second substrates in a plurality of second predetermined positions may further be included in such biochips, wherein each of the plurality of second substrates belongs to a class selected from the group consisting of a polypeptide, a polynucleotide, a carbohydrate, and a pharmacologically active molecule, and wherein the class of each of the first substrates and the class of each of the second substrates is not the same. Particularly contemplated biochips are described in co-pending US Patent Application with the serial number 09/735402 (filed December 12, 2000) and copending PCT application with the serial number PCT/US01/47991 (filed December 11, 2001), both of which are incorporated by reference herein.

Contemplated biochips may further be disposed in a housing (which may or may not be closed), and particularly preferred biochips comprise a housing at least partially enclosing a multi-substrate chip that includes a reference marker and a plurality of substrates in predetermined positions, wherein the reference marker is illuminated by a first light source at a first angle, and wherein at least one of the plurality of substrates is illuminated by a second light source at a second angle, and wherein the housing is configured such that the

first angle and the second angle are not identical. Further particularly contemplated biochips are described in co-pending PCT application with the serial number PCT/US02/03917 (filed January 24, 2002), which is incorporated by reference herein.

As further used herein, the term "analyte" refers to a molecule or assembly of molecules whose presence, quantity, or activity is to be determined from a sample. Particularly contemplated analytes include natural and synthetic nucleic acids, natural and synthetic peptides, pharmacologically active molecules, biological effectors, viruses and portions thereof, bacterial cells and portions thereof, and eukaryotic cells and portions thereof.

For example, where the analyte comprises a natural or synthetic nucleic acid, suitable analytes include oligo- and polynucleotides, DNA and RNA (*e.g.*, cDNA, amplified DNA, in-vitro transcripts, tRNA, rRNA, etc.), nucleic acid analogs (*e.g.*, peptide nucleic acids, phosphorothioate nucleic acids, etc.) and covalent and non-covalent complexes of nucleic acid with functional or non-functional moieties (*e.g.*, radioisotopes, biotin, fluorophor, etc.). Similarly, where the analyte comprises a natural or synthetic peptide, suitable peptides include oligopeptides (*e.g.*, 2-20 amino acids), polypeptides (*e.g.*, 21-20000 amino acids, and higher), linear, cyclic, and/or branched peptides that may include natural and/or non-natural amino acids (in D- or L-configuration), and covalent and non-covalent complexes of peptides with functional or non-functional moieties (*e.g.*, glycoproteins, lipoproteins, biotin, radioisotope labels, etc.).

Contemplated pharmacologically active molecules includes those that interact with reproduction, structural integrity, and/or metabolism of a cell. Consequently, suitable molecules include those interacting with various biological processes including apoptosis, mitosis or meiosis, tubulin assembly and disassembly, enzyme inhibitors or activators, and cis-and trans acting regulatory elements for DNA/RNA expression. Biological effectors particularly include secreted effectors for various organ and systemic functions and include hormones, cytokines, chemokines, and antibodies. With respect to viruses, bacterial and eukaryotic cells it should be recognized that all known viruses, one or more bacterial and eukaryotic cells and fragments thereof (*e.g.*, membranes and their components, ribosomes

and their components, various organelles and their components, etc.) are contemplated suitable for use herein. Further contemplated analytes may also include tissue, and especially animal tissue.

In a further especially contemplated aspects, analytes may also be characterized in their ability to (specifically) bind to one or more substrates, wherein the term "binding of the analyte" refers of a non-covalent interaction between the analyte and a substrate to form a complex having a dissociation constant K_D of equal or less than $10^{-4}M$ at physiological pH, $20^{\circ}C$, and total salt concentration of less than 150 mM. It should further be appreciated that the term "binding of the analyte" specifically includes binding of a substrate to an enzyme at the active site of the enzyme. Consequently, the term "substrate" as used herein refers to any composition, molecule or assembly of molecules that can bind an analyte to form a complex having a dissociation constant K_D of equal or less than $10^{-4}M$ at physiological pH, $20^{\circ}C$, and total salt concentration of less than 150 mM. Particularly preferred substrates include natural and synthetic nucleic acids (*e.g.*, oligonucleotides), natural and synthetic peptides and especially antibodies (and fragments thereof), enzymes, small molecules, viruses or fragments thereof, and one or more bacterial and eukaryotic cells and fragments thereof (*e.g.*, membranes and their components, ribosomes and their components, various organelles and their components, etc.) are contemplated suitable for use herein. Further contemplated substrates may also include tissue, and especially animal tissue.

Thus, the term "non-analyte" refers to any composition, molecule, or assembly of molecules that is not an analyte either by virtue of lack of specific binding and/or by virtue of the chemical composition. For example, where a sample comprises a cytokine and a ribosomal protein, and wherein the substrate comprises an antibody directed against the cytokine, the cytokine will act as the analyte and the ribosomal protein will act as the non-analyte. However, it should be recognized that a sample may also comprise molecules that bind to a substrate with relatively high affinity wherein only one of the molecules is an analyte and the other molecules is not analyte (*e.g.*, single stranded nucleic acid with single base pair mismatch in complementarity relative to a substrate and a single stranded nucleic

P. 0001

Attorney Docket No.: 100788.0011PCT

- 11 -

acid with perfect complementarity relative to the substrate). Here, depending on the test conditions, the analyte may be only one of the analytes or both of the analytes.

Figure 1A schematically depicts an exemplary integrated micro array system 100 having a housing 110 in which a robotics assembly 120 controls motion of automatic pipette 124 and secondary actuator 122 that controls motion of automatic actuator 123. Fluidics station 130 includes a plurality of multi-reagent packs 132. Sample station 140 preferably comprises a plurality of sample vessels 142 (*e.g.*, a microplate with microwells). Pipette tip storage area 150 includes disposable pipette tips for the automatic pipette 124, and magazine holder 160 includes a plurality of magazines 162 that store at least two, and more typically at least eight biochips. The biochips are moved from the magazine to 162 to a sample processing platform 170 (which may further include an energy source such as an ultrasound source, a microwave source, a heater, and/or a cooler), where the biochip may receive the sample pipetted from the sample vessel 142. Alternatively, a stringency station 181 may be included to achieve higher hybridization specificity (*e.g.*, a thermo element that provides heat and/or cooling to the biochip when position on the stringency station). Subsequent steps of incubation, heating, cooling, adjusting of stringency, and/or washing are then performed on the biochip while the biochip is on the sample processing platform to promote binding of the analyte to the substrate, and to remove non-analytes from the platform. Reagents needed for such sample manipulation steps (including staining reagents for bound analytes) are advantageously retrieved from multi-reagent packs 132. Once the analyte is properly processed on the biochip, the biochip is moved from the platform to the optical detector 180 via automatic actuator 123 for detection and/or quantification of the analyte. A data transfer device 190 is electronically coupled to various components of the analytical device and provides data to a remote system or person other than the operator (not shown). A perspective view of an exemplary analytical device is depicted in **Figure 1B**.

Thus, in one particularly preferred aspect of the inventive subject matter, a method of analyzing an analyte on a biochip will include a step in which an analytical device is provided that has a first section and a second section, and wherein both sections receive a biochip having a plurality of substrates in a plurality of predetermined positions. In another

step, the biochip is contacted in the first section with a sample containing a non-analyte and an analyte under conditions that allow binding of the analyte to at least one of the substrates. In yet another step, the first section is operationally coupled to the second section such that the biochip is automatically transferred from the first section to the second section, and in still another step, binding of the analyte to the at least one of the substrates on the biochip is optically detected in the second section.

Particularly contemplated analytical devices include those in which detection and at least one of (a) sample application to the biochip, (b) binding of an analyte to a substrate on the biochip, (c) adjusting the hybridization stringency (*e.g.*, via change in temperature of the analyte substrate complex, or change in ionic strength in the environment of the analyte substrate complex, or change in solvent), and (d) washing the biochip such that the analyte remains bound and at least 75% (more typically at least 95%, and most typically at least 99%) of the non-analyte is washed off the biochip are performed within the same device, preferably without user intervention (*i.e.*, without a user manually manipulating the biochip). Further especially contemplated analytical devices include integrated micro array systems that may further comprise at least one of a sample processing platform, one or more multi-reagent packs, a robotics assembly, and an optical or other detector.

With respect to the first section it is contemplated that such sections may have various configurations so long as such first sections are configured to receive a biochip, wherein the biochip can be contacted with a sample containing a non-analyte and an analyte under conditions that allow binding of the analyte to at least one of the substrates on the biochip. Consequently, particularly suitable first sections will include a generally flat surface that engages with the biochip, or may include at least one guide element (*e.g.*, a rail, a protrusion, or other element) that engages with the biochip to receive and retain the biochip in a predetermined position. For example, appropriate first sections may be shaped in form of a generally flat platform, a U-shaped tray that receives the biochip. Furthermore, it should be appreciated that contemplated first sections may be configured such that they receive at least a second biochip, and in especially preferred aspects, suitable first sections will be configured to receive typically between one and 10 biochips.

PATENT

Attorney Docket No.: 100788.0011PCT

- 13 -

Particularly preferred first sections may be configured to provide preselected conditions that allow binding of the analyte to at least one of the substrates. For example, suitable first sections may be coupled to an energy source that provides energy to the biochip (and thus to the substrate-analyte complex) directly or indirectly. Where direct energy transfer is desired, the energy source may include thermal radiation/convection and/or electromagnetic radiation (*e.g.*, a microwave source) to deliver the energy to the substrate-analyte complex on the biochip. Alternatively, direct energy sources may also include ultrasound probes that contact a fluid in the biochip, wherein the fluid includes the substrate-analyte complex.

On the other hand, where indirect energy transfer is desired, suitable energy sources include thermal elements (*e.g.*, Peltier element, heater, or cooler) or other heater and/or cooler elements that provide heat or cooling to the substrate-analyte complex on the biochip through the first section. For example, suitable first sections may be fabricated from aluminum and may include a Peltier element coupled on one side, while the biochip will be disposed on the opposite side.

In still further especially preferred aspects, the biochip is provided to the first section from a magazine using an automatic actuator that moves the biochip from the magazine along at least one coordinate to the first section (the magazine is preferably disposed within the analytical device). For example, a magazine may be positioned proximal to the first section and include two openings, wherein the actuator is directed into the first opening and the biochip proceeds through the second opening onto the first section (*e.g.*, sample processing platform). However, in alternative aspects, the biochip may also be provided to the first section manually by the user or automatically via any appropriate feeding mechanism. For example, contemplated feeding mechanisms include chutes, conveyor belts, etc. Moreover, it should be recognized that the first section may be moved relative to the second section (or other component in the analytical device), and it is especially preferred that the first section is movable along at least one coordinate in the analytical device (*e.g.*, on a rail moved by a stepper motor)

With respect to the second section, it is generally preferred that the second section will receive the biochip (preferably directly from the first section) and further comprises an optical detector that detects binding of the analyte to the substrate on the biochip. Thus, suitable second sections will be located within the analytical device in a position proximal to the first section and are preferably configured such that the biochip can be directly and automatically moved from the first to the second section (*e.g.*, include a generally horizontal surface, guide rail or other element that engages with the biochip to receive and retain the biochip).

For example, direct and automatic movement (*i.e.*, movement without the user manually moving the biochip) of the biochip may include horizontally moving the biochip from an adjacent first platform to the second platform using an automatic actuator or a conveyor belt-type mechanism. On the other hand, direct and automatic movement of the biochip may also include sliding the biochip from a level that is higher than the second section to the second section (*e.g.*, by tilting the first section). Alternatively, movement of the biochip may also include direct and automatic transfer of the biochip from the first section to the second section using a robotic assembly that controls movement of the biochip along two, and more typically three coordinates.

Furthermore, it is contemplated that suitable second sections may be in a fixed or movable position within the analytical device, and where the second section is movable, it is contemplated that movement of the second section may be along one, two, or three coordinates. Moreover, it is contemplated that in preferred aspects of integrated micro array systems at least one environmental parameter in the second section may be controlled. For example, in particularly contemplated configurations of second sections, temperature and humidity may be controlled (*e.g.*, via Peltier element and/or humidifier).

Contemplated optical detectors generally include all optical devices that can detect an optical signal in a predetermined position on the biochip, and especially contemplated detectors include a photomultiplier tube, a charge coupled device (CCD), which may be optically coupled to a confocal, and/or dark field microscope. Contemplated optical signals detected by such optical detectors include a fluorescence signal, a chemiluminescence signal,

and/or a phosphorescence signal. There are numerous optical detectors known in the art to detect optical signals from biochips, and all of the known devices are considered suitable for use herein. In further preferred configurations, the biochip includes a reference marker that produces a reference signal upon illumination, and the optical detector is focused using a reference signal (*infra*).

Therefore, depending on the particular configuration of first and second sections, it should be appreciated that there are numerous configurations of operational coupling the first section to the second section. However, it is generally contemplated that all modes of operational coupling will allow automatic transfer of the biochip from the first to the second section. The term "automatic transfer" of the biochip as used herein means that the biochip is moved from the first to the second section without a user manually contacting and/or moving the biochip. Consequently, operational coupling may be achieved by positioning the first and second sections relative to each other such that a biochip may be automatically transferred (*e.g.*, via robotic assembly, conveyor belt, or actuator that moves in one or more directions) from the first to the second section, wherein contemplated positioning may include a fixed position of one section relative to the other section (*e.g.*, first and second sections are in a fixed and abutting position), or a movable positioning where one section moves relative to the other section (*e.g.*, first section moves along a guide rail actuated by a motor into abutting position with the second section).

Suitable analytical devices may further include various sensors that provide a computer (electronically coupled to the analytical device and controlling at least some of the functions [*e.g.*, length and temperature of incubation steps, type of assay performed, data analysis, etc.] of the analytic device) with environmental information, and especially preferred sensors include a humidity sensor and/or a temperature sensor. Yet further contemplated sensors may include barcode readers, and it is especially preferred that the barcode reader(s) will read barcodes on at least one of the reagent pack, the biochip, and the sample container.

With respect to contemplated biochips, it is generally contemplated that suitable biochips will include a carrier to which a plurality of substrates in predetermined positions

P. NT

Attorney Docket No.: 100788.0011PCT

- 16 -

are coupled, wherein at least one of the substrates is capable of selectively binding an analyte. One class of particularly preferred biochips includes a carrier coupled to a multi-functional matrix layer that is coupled to a substrate, wherein the multi-functional matrix layer provides reduction of at least one of an autofluorescence of the carrier, an incident-light-absorption of the carrier, a charge-effect of the carrier, and a surface unevenness of the carrier, and wherein the substrate binds to an analyte that is disposed in a sample fluid when the sample fluid contacts the biochip.

Alternatively, another class of especially contemplated biochips comprises a plurality of first substrates in a plurality of first predetermined positions, wherein each of the plurality of first substrates belongs to a class selected from the group consisting of a polypeptide, a polynucleotide, a carbohydrate, and a pharmacologically active molecule. A plurality of second substrates in a plurality of second predetermined positions may further be included in such biochips, wherein each of the plurality of second substrates belongs to a class selected from the group consisting of a polypeptide, a polynucleotide, a carbohydrate, and a pharmacologically active molecule, and wherein the class of each of the first substrates and the class of each of the second substrates is not the same. In especially contemplated aspects, at least one of the plurality of substrates is non-covalently coupled to the biochip via a crosslinker. Particularly contemplated biochips are described in co-pending US Patent Application with the serial number 09/735402 and copending PCT application with the serial number PCT/US01/47991 (*supra*).

Contemplated biochips may further be disposed in a housing (which may or may not be closed), and particularly preferred biochips comprise a housing at least partially enclosing a multi-substrate chip that includes a reference marker and a plurality of substrates in predetermined positions, wherein the reference marker is illuminated by a first light source at a first angle, and wherein at least one of the plurality of substrates is illuminated by a second light source at a second angle, and wherein the housing is configured such that the first angle and the second angle are not identical. Further particularly contemplated biochips are described in co-pending PCT application with the serial number PCT/US02/03917 (*supra*).

In especially preferred aspects of contemplated methods, a second biochip with a plurality of second substrates in a plurality of predetermined positions may be provided to at least one of the first and second sections, and the second biochip is contacted in the first section with a sample containing a second non-analyte and a second analyte under conditions that allow binding of the second analyte to at least one of the second substrates of the second biochip. While not limiting to the inventive subject matter, it is contemplated that the substrates of the first biochip and the second biochip belong to different classes. For example, while the first biochip may include nucleic acids as substrates, the second biochip may include peptides as a substrate. Of course, it should also be recognized that contemplated biochips may also include at least two different types of substrates, wherein contemplated types of substrates include nucleic acids, peptides, small molecules, pharmaceutically active molecules, a virus, bacterial or eukaryotic cell or fragments thereof, and tissues. Consequently, particularly preferred samples include biological fluids (*e.g.*, whole or processed blood, plasma, serum, biopsy specimens, urine, spinal fluid, saliva, etc.), wherein particularly preferred analytes include tissues, nucleic acids, peptides, and enzyme inhibitors.

Depending on the particular type of sample and/or substrate on the biochip, it is generally contemplated that the step of contacting the biochip with the sample includes an automatic application, however, manual application of the sample to the biochip is also considered suitable. In a particularly preferred aspect, the sample is a liquid and is pipetted with an automatic pipette (*i.e.*, aspiration of the fluid is performed using a motor or electric vacuum pump) that is disposed within the analytical device. There are numerous automatic pipettes known in the art and all of the known automatic pipettes are considered suitable for use herein. Especially preferred automatic pipettes are Gilson, Eppendorf, and Rainin automatic pipettors, which may or may not be further modified.

Particularly preferred modifications of contemplated automatic pipettes will include at least one of a volume sensor and a tip height sensor. For example, one particularly preferred volume sensor may employ a laser beam within the pipette tip, wherein the laser beam is employed to determine the height (and with this the volume) of the aspirated liquid

within the tip. Another especially preferred aspect includes an ultrasound (or second laser) beam that is employed to determine the distance between the fluid dispensing end of the pipette tip and a surface to which the fluid is to be dispensed.

With respect to the step optically detecting binding of the analyte, it is generally contemplated that all known detection methods are suitable for use herein. However, in particularly preferred detection steps, non-analytes are removed from the biochip prior to detection by providing conditions that promote dissociation or non-binding of the non-analyte. For example, suitable conditions may include washing with wash fluids (*e.g.*, provided by a multi-reagent pack), a temperature change (*e.g.*, heating), sonication, etc. Optical detection of binding may be performed using detection of radiation, luminescence, or light absorption of a dye or other marker that is coupled to the analyte (wherein the step of coupling the dye or other marker may be performed in a separate step).

Particularly preferred detections include detection of chemiluminescence, fluorescence, and/or phosphorescence, which may be performed using a photomultiplier in conjunction with a dark field microscope or confocal microscope (which may be located in a separate section or the section). Especially preferred optical detection includes a step in which the focal plane is determined in a process that avoids illumination (and therefore photo-bleaching) of the analyte that is bound to the substrate.

Thus, in another especially preferred aspect of the inventive subject matter, a method of analyzing an analyte on a biochip may include providing a biochip with a reference marker and a plurality of substrates, wherein at least one of the substrates binds an analyte, illuminating the reference marker to create a reference signal, and illuminating the analyte to create an analyte signal, determining a focal plane for an optical detector using the reference signal and adjusting the optical detector to the focal plane, and acquiring the analyte signal using the optical detector.

With respect to the biochip, the same considerations as discussed above apply. Particularly contemplated biochips will include at least one, more preferably two, and most preferably four reference markers (which may be positioned at the corners of the biochip),

wherein suitable reference markers include numerous optically detectable elements. Among other elements, suitable reference markers include fluorophors, luminogenic substrates, and phosphorescent compounds. Alternatively, dye of dye mixtures may also be suitable.

Furthermore, appropriate biochips may have one or more classes of substrates (which may or may not be chemically distinct), and contemplated substrates include nucleic acids, peptides, and enzyme inhibitors, wherein at least one of the substrates is non-covalently coupled to the biochip via a crosslinker. Especially preferred crosslinkers include known affinity pairs, which may comprise peptides or small molecules. For example, contemplated crosslinkers are biotin/streptavidin, antibody (fragment)/hapten, chelated nickel/polyHistidyl moiety, etc., wherein either of the affinity pair may be (covalently or non-covalently) coupled to the biochip. Consequently, binding of the analyte to the substrate is preferably non-covalent binding, however, covalent binding is not excluded.

In further preferred aspects, the biochip is moved within the analytical device from a sample processing platform (e.g., the first section, *supra*) to a detector (e.g., in the second section, *supra*) using an automatic actuator. Contemplated automatic actuators include robotic actuators that are controlled in at least two, and more preferably three dimensions via step motors. However, other means of moving are also contemplated suitable and include conveyor belts, slides, etc.

Contemplated steps of illuminating the reference marker may be performed in numerous manners so long as the reference marker receives sufficient light to enable optical detection and focusing. Thus, suitable illumination of the reference marker includes dark field illumination (e.g., through the housing of the biochip), which is particularly preferably where the analyte comprises a light-sensitive marker. However, direct illumination of the reference marker is also contemplated suitable for use herein. Consequently, the light sources for illumination may vary considerably and may include illumination of the reference marker with a light source other than the light source employed for illumination of the analyte. Exemplary light sources include various laser and laser diodes, LED diodes, incandescent and fluorescent light sources, etc.

PATENT

Attorney Docket No.: 100788.0011PCT

- 20 -

Therefore, the reference marker may be employed to determine the focal plane of the detection device (preferably confocal microscope) by illuminating the reference marker which is in known spatial relationship to the position of the analyte. Consequently, and especially where more than one reference marker is employed, correct focusing of analytes disposed on an uneven surface of the biochip is possible without an otherwise required step of refocusing to each new analyte. Furthermore, the use of an independent reference marker will advantageously allow illumination of the biochip (for focusing purposes) with light at a wavelength that will provide significantly reduced photo-damage to the analyte, or even no photo-damage at all. Adjustment of the optical detector may be performed in various manners and will typically include a relative movement between the optical detector and the biochip in at least one dimension. However, it is generally preferred that the biochip is moved within the detection unit on a platform that can be moved in at least one dimension, and more typically on a platform that can be moved in all three dimensions.

Thus, the analyte signal (which may be directly generated by the analyte or indirectly by a marker coupled to the analyte) includes signals selected from the group consisting of a fluorescence signal, a chemiluminescence signal, and a phosphorescence signal. The particular nature of the signal will typically be determined at least in part by the particular analyte, and a person of ordinary skill in the art will readily determine the appropriate signal source.

In a still further especially contemplated aspect of the inventive subject matter, and particularly where the analytical device includes a data transfer interface, the inventors contemplate a method of operating an analytical device that includes a step of providing an analytical device comprising a data transfer interface coupled to at least one of a detector, a multi-reagent pack, an automatic pipette, and a sample processing platform, electronically coupling the data transfer interface with a person other than a user of the analytical device, providing data from at least one of the detector, the multi-reagent pack, the automatic pipette, and the sample processing platform to the person via the data transfer interface, and using the data to analyze operational status of the analytical device.

PATENT

Attorney Docket No.: 100788.0011PCT

- 21 -

Especially suitable data transfer interfaces include electronic data transfer interfaces used in personal computers such as telephone or cable modems. Consequently, suitable data transfer interfaces are preferably controlled by a microprocessor (most preferably the microprocessor that controls operation of the analytic device) within the analytical device. In a particularly contemplated mode of operation, the data transfer interface is temporarily electronically connected to a remote computer via a telephone modem, wherein either the analytical device or the remote compute initiates electronic communication.

In particularly contemplated aspects, the data transfer interface is electronically coupled to the detector, a multi-reagent pack, the automatic pipette, and/or the sample processing platform, wherein the data transfer interface receives or provides data from the detector, multi-reagent pack, automatic pipette, and/or sample processing platform. For example, the detector may provide data relating to signal strength, wavelength, calibration signals, or type of assay to the interface, while the multi-reagent pack may provide data regarding the (remaining) contents of the reagents in the pack, the type of test performed, the date the pack was purchased and/or first used, etc. Similarly, the automatic pipette may provide data relating to number of pipetting functions, size of tips employed, etc. Thus, the data transfer interface may collect and/or disseminate data that are relevant for the operational status of the analytical device. Consequently, it should be appreciated that the data transfer interface is a bi-directional data transfer interface, that is, data are provided to and from the analytical device.

Consequently, in one aspect of the inventive subject matter, the data transfer interface may be electronically coupled to a person other than the user of the analytical device to provide data from the detector, multi-reagent pack, automatic pipette, sample processing platform, or other component (hard drive, CPU, pipette rack, etc.). Such configurations may be especially advantageous where an analytical device has become inoperable or provide a user with an error notification. The user may then activate electronic communication (manually or by default) between the data transfer interface and a computer in a remote location, wherein a person other than the user (*e.g.*, service technician) request or receives the status data to provide immediate diagnosis of the analytical device from a

PACONT

Attorney Docket No.: 100788.0011PCT

- 22 -

remote location. The term "person other than the user" as used herein refers to a person does not initiate, continue, or terminate (including analysis of test results) a test using the analytical device, typically while proximal to the analytical device. The term "proximal to the analytical device" as used herein means within the same room, or associated with the data generated by the analytical device (*e.g.*, a physicians office). Thus especially contemplated persons other than a user include sales staff for components or reagents of the analytical device, service technicians of the analytical device, etc.

With respect to the step of providing the data, it should be recognized that all known methods of data transfer are contemplated, particularly including the person other than the user remotely requesting data, and the user initiating electronic communication between the analytical device and the person other than the user. Thus, the step of providing may preferably be executed via an Internet or via a modem connection and may be performed in response to an action of the user of the analytical device.

Particularly contemplated data include type of reagent in the multi-reagent pack, volume of at least one reagent in the multi-reagent pack, volume of liquid transferred using the automatic pipette, temperature of the sample processing platform, type of test performed using the analytical device, batch number of reagent in the multi-reagent pack, date manufactured of reagent in the multi-reagent pack, and expiration date of reagent in the multi-reagent pack. Consequently, the operational status will include inoperability (*e.g.*, inoperable due to lack of reagent, inoperable due to failure of the automatic pipette, inoperable due to incompatibility of reagent with a selected test, and/or inoperable due to failure of the detector) of the analytical device, current activity of the analytical device (*e.g.*, pipetting, focusing, detecting, etc.), and supply status (*e.g.*, how many test reagents left).

Therefore, a further particularly contemplated aspect of the inventive subject matter includes a method of marketing in which an analytical device is provided, wherein the device comprises a data transfer interface that receives status data of a component in the analytical device. The data transfer device is then electronically coupled to a system in a remote location relative to the analytical device, and the data transfer device provides then the status data to the remote system using the data transfer interface, wherein the status data

are used in the remote system (or analytical device) to initiate delivery of a replacement for the component.

With respect to the analytical device, the data transfer interface, status data, the component, the same considerations as discussed above apply. Particularly preferred analytical devices include those that analyze binding of an analyte to a substrate on a biochip. However, numerous other analytical devices are also considered suitable and include analytical and/or preparative systems (*e.g.*, HPLC, GC, etc.). Further especially preferred components include reagents (solid, liquid, or gaseous), wherein the status data of the component is (remaining) volume of the reagent in the analytical device. However, non-reagent components, and especially disposable non-reagent components are also contemplated. Thus suitable components include pipette tips, wherein the status data of the component is the number of remaining pipette tips in the analytical device

It should further be recognized that the step of electronically coupling may include a permanent coupling or a temporary coupling (*e.g.*, user, or device initiated). However, especially suitable couplings include coupling the analytical device with an Internet. In further contemplated aspects, the step of providing the status data is controlled by a predetermined schedule executed on a processor of the analytical device. Alternatively, the step of providing the status data may be controlled by a predetermined schedule executed on a processor of the system in the remote location.

It is generally contemplated that the status data may be used in the remote system (or in the analytical device) to initiate delivery of a replacement for the component. The term "initiate delivery" as used herein refer to an event leading to a decision whether or not to provide a customer with a product. Thus, initiation of delivery may include automatic generation of a purchase order, automated offer to purchase from the remote system to the analytical device, etc. Consequently, contemplated methods and configurations may be employed for inventory control and management on the side of the operator of the analytical device.

Therefore, contemplated systems will provide an operator with the capability to quantitatively and qualitatively analyze one or more analytes in one or more sample with minimum manual intervention. For example, while numerous known systems separate sample and/or analyte handling (*e.g.*, application, washing, hybridization) from analyte detection, the contemplated system will in one preferred aspect perform sample and/or analyte handling and analyte detection in an automated and typically continuous manner.

Thus, contemplated systems will include the following subsections: Sample and reagent handling, disposable handling, microarray processing, stringency station, optical detection system, waste handling, and data/result analysis. These sections handle all the processing required for DNA and Proteomic analysis for the following not exclusive list: SNP and STR analysis, microsatellite analysis, gene- and protein expression analysis, and protein quantification and identification.

Consequently, one or more of the following processing steps may be included in contemplated analytic systems: Sample and reagent dispensing operations, analysis of environmental conditions for sample and reagent, wash processes using aspiration dispenser, ultrasonic energy and heat, use of ultrasonic energy for mixing to improve hybridization and binding, bar code for reagent tracking and sample identification, sonic irradiation for chip surface detection, laser irradiation for volume and surface detection, and the use of a reagent module as a communication link between at least two of manufacturing, assay development scientist, user and technical support without any intervention from the operator. In further contemplated aspects, stringency is preferably controlled at least in part determined by heat (*e.g.*, thermal stringency for improving specificity), and optical detection employs a two wavelength system for excitation and detection using confocal microscope technology. Assay development software is contemplated to assist in automation of new tests.

In yet further contemplated aspects, the software/operator interface will provide the system with specific test requirement for a specific sample, which may be downloaded from a host computer. Furthermore, it is contemplated that the interface may also be used to transmit results through web or modem. Thus, a contemplated operation communication link

PATENT

Attorney Docket No.: 100788.0011PCT

- 25 -

may include an integrated color monitor, a mouse and keyboard, a R/W CD, 40 GB of hard drive, and bioinformatics software for data/result analysis.

Thus, specific embodiments and applications of integrated micro array systems have been disclosed. It should be apparent, however, to those skilled in the art that many more modifications besides those already described are possible without departing from the inventive concepts herein. The inventive subject matter, therefore, is not to be restricted except in the spirit of the appended claims. Moreover, in interpreting both the specification and the claims, all terms should be interpreted in the broadest possible manner consistent with the context. In particular, the terms "comprises" and "comprising" should be interpreted as referring to elements, components, or steps in a non-exclusive manner, indicating that the referenced elements, components, or steps may be present, or utilized, or combined with other elements, components, or steps that are not expressly referenced.

CLAIMS

What is claimed is:

1. A method of analyzing an analyte on a biochip, comprising:

providing an analytical device comprising a first section and a second section that receive a biochip having a plurality of substrates in a plurality of predetermined positions;

contacting the biochip in the first section with a sample containing a non-analyte and an analyte under conditions that allow binding of the analyte to at least one of the substrates;

operationally coupling the first section to the second section such that the biochip is automatically transferred from the first section to the second section; and

optically detecting in the second section binding of the analyte to the at least one of the substrates on the biochip.
2. The method of claim 1 wherein the biochip is provided to the first section from a magazine using an automatic actuator, wherein the magazine is disposed within the analytical device.
3. The method of claim 1 wherein the first section is configured to receive at least a second biochip.
4. The method of claim 1 wherein the first section further comprises an energy source.
5. The method of claim 4 wherein the energy source is selected from the group consisting of an ultrasound source, a microwave source, a heater, and a cooler.
6. The method of claim 1 wherein the sample comprises a biological fluid, and wherein the analyte is selected from the group consisting of a tissue, a nucleic acid, a peptide, and an enzyme inhibitor.

7. The method of claim 1 wherein the plurality of substrates comprise at least one of a nucleic acid, a peptide, and an enzyme inhibitor, and wherein at least one of the plurality of substrates is non-covalently coupled to the biochip via a crosslinker.
8. The method of claim 1 wherein the step of contacting includes pipetting the sample with an automatic pipette that is disposed within the analytical device.
9. The method of claim 1 wherein the step of contacting includes heating the biochip within the analytical device.
10. The method of claim 1 wherein the step of operationally coupling includes providing an automatic actuator that moves the biochip from a first platform of the first section to a second platform of a second section.
11. The method of claim 1 wherein the step of optically detecting includes a confocal microscope or a dark field microscope.
12. The method of claim 1 wherein the step of optically detecting further comprises focusing an optical device using a reference signal from a reference marker that is disposed on the biochip.
13. The method of claim 1 wherein the step of optically detecting comprises detecting a signal selected from the group consisting of a fluorescence signal, a chemiluminescence signal, and a phosphorescence signal.
14. The method of claim 1 further comprising:

providing a second biochip having a plurality of second substrates in a plurality of predetermined positions;

contacting the second biochip in the first section with a sample containing a second non-analyte and a second analyte under conditions that allow binding of the second analyte to at least one of the second substrates of the second biochip;

wherein the plurality of substrates comprises a nucleic acid, and wherein the plurality of second substrates comprises a peptide.

15. A method of analyzing an analyte on a biochip, comprising:

providing a biochip with a reference marker and a plurality of substrates, wherein at least one of the substrates binds an analyte;

illuminating the reference marker to create a reference signal, and illuminating the analyte to create an analyte signal;

determining a focal plane for an optical detector using the reference signal and adjusting the optical detector to the focal plane; and

acquiring the analyte signal using the optical detector.
16. The method of claim 15 wherein the reference marker comprises a compound selected from the group consisting of a fluorophor, a luminogenic substrate, or a phosphorescent compound.
17. The method of claim 15 wherein the at least one of the substrates is selected from the group consisting of a nucleic acid, a peptide, and an enzyme inhibitor, and wherein the at least one of the substrates is non-covalently coupled to the biochip via a crosslinker.
18. The method of claim 15 wherein the binding of the analyte to the at least one of the substrates is non-covalent binding.
19. The method of claim 15 wherein the step of providing the biochip comprises moving the biochip from a sample processing platform to a detector using an automatic actuator.
20. The method of claim 15 wherein the step of illuminating the reference marker comprises illumination of the reference marker in a dark field.

PATENT

Attorney Docket No.: 100788.001 IPCT

- 29 -

21. The method of claim 15 wherein the step of illuminating the analyte comprises illumination with a laser.
22. The method of claim 15 wherein illuminating the reference marker and illuminating the analyte are performed using independent light sources.
23. The method of claim 15 wherein the optical detector comprises a confocal microscope.
24. The method of claim 15 wherein the analyte signal is a signal selected from the group consisting of a fluorescence signal, a chemiluminescence signal, and a phosphorescence signal.
25. A method of operating an analytical device, comprising:

providing an analytical device comprising a data transfer interface coupled to at least one of a detector, a multi-reagent pack, an automatic pipette, and a sample processing platform;

electronically coupling the data transfer interface with a person other than a user of the analytical device;

providing data from at least one of the detector, the multi-reagent pack, the automatic pipette, and the sample processing platform to the person via the data transfer interface; and

using the data to analyze operational status of the analytical device.
26. The method of claim 25 wherein the person other than the user is in a remote location relative to the analytical device.
27. The method of claim 25 wherein the step of providing is executed via an Internet or via a modem connection.

PATENT

Attorney Docket No.: 100788.001 IPCT

- 30 -

28. The method of claim 25 wherein the step of providing is performed in response to an action of the user of the analytical device.
29. The method of claim 25 wherein the data is selected from the group consisting of type of reagent in the multi-reagent pack, volume of at least one reagent in the multi-reagent pack, volume of liquid transferred using the automatic pipette, temperature of the sample processing platform, type of test performed using the analytical device, batch number of reagent in the multi-reagent pack, date manufactured of reagent in the multi-reagent pack, and expiration date of reagent in the multi-reagent pack.
30. The method of claim 25 wherein the operational status is selected from the group consisting of inoperable due to lack of reagent, inoperable due to failure of the automatic pipette, inoperable due to incompatibility of reagent with a selected test, and inoperable due to failure of the detector.
31. A method of marketing comprising:

providing an analytical device comprising a data transfer interface that receives status data of a component in the analytical device;

electronically coupling the data transfer interface with a system in a remote location relative to the analytical device;

providing the status data to the remote system using the data transfer interface; and

using the status data in the remote system to initiate delivery of a replacement for the component.
32. The method of claim 31 wherein the analytical device analyzes binding of an analyte to a substrate on a biochip.
33. The method of claim 31 wherein the component is a reagent and wherein the status data of the component is volume of the reagent in the analytical device.

PATENT

Attorney Docket No.: 100788.0011PCT

- 31 -

34. The method of claim 31 wherein the component is a pipette tip and wherein the status data of the component is number of remaining pipette tips in the analytical device.
35. The method of claim 31 wherein the step of electronically coupling includes coupling the analytical device with an Internet.
36. The method of claim 31 wherein the step of providing the status data is controlled by a predetermined schedule executed on a processor of the analytical device.
37. The method of claim 31 wherein the step of providing the status data is controlled by a predetermined schedule executed on a processor of the system in the remote location.
38. The method of claim 31 wherein initiation of delivery includes automatic generation of a purchase order.

PATENT

Attorney Docket No.: 100788.001 IPCT

- 32 -

ABSTRACT

Various methods are provided for an integrated micro array system that allows fully automated sample processing and detection/quantification of nucleic acid and protein samples in a single analytical device, which may be configured to communicate data to a

5 person other than the person operating the device.




Figure 1A




FIG. 1B




Figure 2




Figure 3

5/6




Figure 4




Figure 5